Search - tctmd.com

Displaying 1 - 20 of 66

Sort: Relevancy | Date

The Biggest News of 2021: TCTMD’s Top 10

News Opinion Editor's Corner

The Biggest News of 2021: TCTMD’s Top 10

December 30, 2021

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

News Daily News

MICHELLE Published: Low-Dose Rivaroxaban Cuts VTE Risk After COVID-19 Admission

December 29, 2021

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

News Daily News

Apixaban Appears Safer, More Effective Than Rivaroxaban in Medicare Study

December 27, 2021

FDA Approves Two Additional Indications for Rivaroxaban in Children

News Daily News

FDA Approves Two Additional Indications for Rivaroxaban in Children

December 21, 2021

PASCAL Pinpoints Patients With Strokes Causally Related to PFO

News Daily News

PASCAL Pinpoints Patients With Strokes Causally Related to PFO

Yael L. Maxwell

December 20, 2021

COVID-19: TCTMD’s Dispatch for November Week 4

News Daily News

COVID-19: TCTMD’s Dispatch for November Week 4

November 22, 2021

Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage

News Conference News AHA 2021

Racial/Ethnic Disparities in AF Care Persist Despite Dual VA, Medicare Coverage

November 19, 2021

Fitbit Joins the AF Hunt, but Effect on Treatment, Outcomes Unknown

News Conference News AHA 2021

Fitbit Joins the AF Hunt, but Effect on Treatment, Outcomes Unknown

Yael L. Maxwell

November 14, 2021

GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients

News Conference News AHA 2021

GIRAF: Cognitive Outcomes Similar With Dabigatran, Warfarin in Older AF Patients

November 14, 2021

Oral Anticoagulation Should Be the Default Strategy After LAAC

Presentation TCT 2021

Oral Anticoagulation Should Be the Default Strategy After LAAC

Presenter: Matthew J. Price

November 06, 2021

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

News Conference News TCT 2021

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

November 06, 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

November 05, 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

News Conference News TCT 2021

PRAGUE-17: LAA Occlusion Noninferior to DOACs Over Longer Term

November 05, 2021

PRAGUE-17: Three-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure Versus Direct Acting Oral Anticoagulation in Patients With Atrial Fibrillation

Presentation TCT 2021

PRAGUE-17: Three-Year Outcomes From a Randomized Trial of Left Atrial Appendage Closure Versus Direct Acting Oral Anticoagulation in Patients With Atrial Fibrillation

Presenter: Pavel Osmancik

November 05, 2021

Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR

News Daily News

Tendyne at 2 Years: Confirmed Feasibility but High Mortality With TMVR

Yael L. Maxwell

November 03, 2021

Predictors of AF May Help Guide Care After Stroke of Unknown Cause

News Daily News

Predictors of AF May Help Guide Care After Stroke of Unknown Cause

October 26, 2021

Starting DOACs Early After Ischemic Stroke Appears Safe

News Daily News

Starting DOACs Early After Ischemic Stroke Appears Safe

October 21, 2021

More Deaths With Bioprosthetic Than Mechanical AVR in Young AS Patients

News Conference News EACTS 2021

More Deaths With Bioprosthetic Than Mechanical AVR in Young AS Patients

Michael O'Riordan

October 18, 2021

Half-Dose DOAC May Be a Good Post-Watchman Option

News Daily News

Half-Dose DOAC May Be a Good Post-Watchman Option

October 14, 2021

LAA Closure Feasible in Patients With Thrombus: Registry

News Conference News TCT 2021

LAA Closure Feasible in Patients With Thrombus: Registry

Michael O'Riordan

October 13, 2021

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.